Skip to main content
. 2017 Feb 17;31(6):890–898. doi: 10.1038/eye.2017.7

Figure 2.

Figure 2

The mean change in BCVA measured by ETDRS letters (n=47) during the study period (a). (b–c) A subgroup analysis of the mean change in BCVA during the study. (b) BCVA changes in eyes that received additional injection at week 20 (n=35), and in eyes without additional injection (n=12). (c) BCVA changes along the study according to the number of bevacizumab injections prior to enrollment to the study. There were similar BCVA changes in both groups. *P<0.05 for the comparison of current vs follow-up examination. Error bars represent SEM.